Latest Articles
If you’ve ever been dismissed by a doctor, read this book - inews
If you’ve ever been dismissed by a doctor, read this book inews
Published: July 13, 2024, 7 a.m.
Ultrasound Screening Often Misses Endometrial Cancer in Black Females - Healthline
Ultrasound Screening Often Misses Endometrial Cancer in Black Females Healthline
Published: July 9, 2024, 7 a.m.
Bindi Irwin on Her Health: Star Says Endometriosis Symptoms Were "Dismissed" - Distractify
Bindi Irwin on Her Health: Star Says Endometriosis Symptoms Were "Dismissed" Distractify
Published: July 7, 2024, 7 a.m.
Christie's pain was dismissed for decades, then she developed 'terminal' endometriosis - 9News
Christie's pain was dismissed for decades, then she developed 'terminal' endometriosis 9News
Published: July 2, 2024, 7 a.m.
Isha Ambani on Conceiving Twins Through IVF: 5 Misconceptions You Should Stop Believing Now - India.com
Isha Ambani on Conceiving Twins Through IVF: 5 Misconceptions You Should Stop Believing Now India.com
Published: June 29, 2024, 7 a.m.
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology
Published: June 23, 2024, 7 a.m.
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer - OncLive
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma - OncLive
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma OncLive
Published: June 20, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets - The ASCO Post
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets The ASCO Post
Published: June 10, 2024, 7 a.m.
Link copied to clipboard!